Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways
The rise in the incidence of cancer globally has led to a heightened interest in targeted therapies as a form of anticancer treatment. Key oncogenic targets, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and kirsten rat sarcoma viral oncogene homologue...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2024-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/21/12/1141 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539693183401984 |
|---|---|
| author | Li Gong Shixue Yang Junli Huang Yongsheng Li |
| author_facet | Li Gong Shixue Yang Junli Huang Yongsheng Li |
| author_sort | Li Gong |
| collection | DOAJ |
| description | The rise in the incidence of cancer globally has led to a heightened interest in targeted therapies as a form of anticancer treatment. Key oncogenic targets, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and kirsten rat sarcoma viral oncogene homologue (KRAS), have emerged as focal points in the development of targeted agents. Research has investigated the impact of gut microbiota on the efficacy of various anticancer therapies, such as immunotherapy, chemotherapy, and radiotherapy. However, a notable gap exists in the literature regarding the relationship between gut microbiota and targeted agents. This review emphasizes how specific gut microbiota and gut microbiota metabolites, including butyrate, propionate, and ursodeoxycholic acid, interact with oncogenic pathways to modulate anti-tumor effects. Conversely, deoxycholic acid, lipopolysaccharide, and trimethylamine n-oxide may exert pro-tumor effects. Furthermore, modulation of the gut microbiota influences glucose and lipid metabolism, thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors. By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways, this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings. |
| format | Article |
| id | doaj-art-80f024be2b794e9590b530f3cf8d1531 |
| institution | Kabale University |
| issn | 2095-3941 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj-art-80f024be2b794e9590b530f3cf8d15312025-02-05T09:57:37ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412024-12-0121121141115510.20892/j.issn.2095-3941.2024.0320Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathwaysLi Gong0Shixue Yang1Junli Huang2Yongsheng Li3Department of Phase I Clinical Trial Ward, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, ChinaDepartment of Medical Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, ChinaKey Laboratory of Biorheological Science and Technology of Ministry of Education, Bioengineering College, Chongqing University, Chongqing 400044, ChinaDepartment of Phase I Clinical Trial Ward, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, ChinaThe rise in the incidence of cancer globally has led to a heightened interest in targeted therapies as a form of anticancer treatment. Key oncogenic targets, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and kirsten rat sarcoma viral oncogene homologue (KRAS), have emerged as focal points in the development of targeted agents. Research has investigated the impact of gut microbiota on the efficacy of various anticancer therapies, such as immunotherapy, chemotherapy, and radiotherapy. However, a notable gap exists in the literature regarding the relationship between gut microbiota and targeted agents. This review emphasizes how specific gut microbiota and gut microbiota metabolites, including butyrate, propionate, and ursodeoxycholic acid, interact with oncogenic pathways to modulate anti-tumor effects. Conversely, deoxycholic acid, lipopolysaccharide, and trimethylamine n-oxide may exert pro-tumor effects. Furthermore, modulation of the gut microbiota influences glucose and lipid metabolism, thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors. By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways, this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings.https://www.cancerbiomed.org/content/21/12/1141gut microbiotametabolitestargeted therapytumorigenesis pathwayegfrvegfkras |
| spellingShingle | Li Gong Shixue Yang Junli Huang Yongsheng Li Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways Cancer Biology & Medicine gut microbiota metabolites targeted therapy tumorigenesis pathway egfr vegf kras |
| title | Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways |
| title_full | Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways |
| title_fullStr | Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways |
| title_full_unstemmed | Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways |
| title_short | Modulation of gut microbiota in targeted cancer therapy: insights on the EGFR/VEGF/KRAS pathways |
| title_sort | modulation of gut microbiota in targeted cancer therapy insights on the egfr vegf kras pathways |
| topic | gut microbiota metabolites targeted therapy tumorigenesis pathway egfr vegf kras |
| url | https://www.cancerbiomed.org/content/21/12/1141 |
| work_keys_str_mv | AT ligong modulationofgutmicrobiotaintargetedcancertherapyinsightsontheegfrvegfkraspathways AT shixueyang modulationofgutmicrobiotaintargetedcancertherapyinsightsontheegfrvegfkraspathways AT junlihuang modulationofgutmicrobiotaintargetedcancertherapyinsightsontheegfrvegfkraspathways AT yongshengli modulationofgutmicrobiotaintargetedcancertherapyinsightsontheegfrvegfkraspathways |